Ki-67 作为弥漫性大 B 细胞淋巴瘤预后标志物的评估：一项单中心回顾性队列研究。
Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort Study.
机构信息
Karl Landsteiner University of Health Sciences, 3500 Krems, Austria.
Department of Internal Medicine 2, University Hospital Krems, 3500 Krems, Austria.
出版信息
Curr Oncol. 2021 Nov 8;28(6):4521-4529. doi: 10.3390/curroncol28060383.
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and prognostic information is essential in finding the right treatment. This study evaluated the prognostic significance of Ki-67 in patients with DLBCL.
METHODS
Patients with DLBCL, treated with first-line R-CHOP, were retrospectively analyzed in groups of high (>70%) and low (≤70%) Ki-67. Parameters of interest were the international prognostic index (IPI), treatment response, progression-free survival (PFS) and overall survival (OS). A chi-squared test or Fisher's exact test was conducted to analyze categorical variables. Kaplan-Meier and log-rank tests were applied for survival analyses. Finally, a multivariate linear regression analysis was performed, including gender, Ki-67 ≤ 70% or >70%, IPI and presence of B symptoms.
RESULTS
Overall, 58 patients were included. No significant association was found between Ki-67 status and IPI ( = 0.148) or treatment response ( = 0.373). Survival in patients with high Ki-67 was significantly inferior with respect to OS ( = 0.047) but not PFS ( = 0.138). Multivariate linear regression, however, yielded only IPI as a risk factor for OS.
CONCLUSION
Future studies with larger patient cohorts are needed in order to elucidate the prognostic role of Ki-67 in patients with DLBCL treated with R-CHOP.
背景
弥漫性大 B 细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤，预后信息对于找到正确的治疗方法至关重要。本研究评估了 Ki-67 在 DLBCL 患者中的预后意义。
方法
回顾性分析了接受一线 R-CHOP 治疗的 DLBCL 患者，分为 Ki-67 高（>70%）和低（≤70%）组。感兴趣的参数包括国际预后指数（IPI）、治疗反应、无进展生存期（PFS）和总生存期（OS）。采用卡方检验或 Fisher 确切检验分析分类变量。采用 Kaplan-Meier 和对数秩检验进行生存分析。最后，进行了多变量线性回归分析，包括性别、Ki-67≤70%或>70%、IPI 和 B 症状的存在。
结果
共纳入 58 例患者。Ki-67 状态与 IPI（ = 0.148）或治疗反应（ = 0.373）之间无显著相关性。高 Ki-67 患者的 OS 显著降低（ = 0.047），但 PFS 无显著差异（ = 0.138）。然而，多变量线性回归仅显示 IPI 是 OS 的危险因素。
结论
需要更大的患者队列研究来阐明 Ki-67 在接受 R-CHOP 治疗的 DLBCL 患者中的预后作用。
Zotero 插件